Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447286 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05447286: Completed Phase 1 study, sponsored by Yale University.
NCT05447286 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447286, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.
Primary Outcome
Change in respiratory rate pre and post drug administration measured by counting breaths
Interventions
- DRUG Placebo
- DRUG Oxycodone
- DRUG NYX-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the finished NCT05447286 record still lists
NCT05447286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05447286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05447286 about?
NCT05447286 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study". This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals ...
What is the current status of trial NCT05447286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-05-15. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT05447286?
The interventions under investigation include: Placebo (DRUG), Oxycodone (DRUG), NYX-783 (DRUG).
Who is sponsoring clinical trial NCT05447286?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05447286's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI